The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | EGR1 as a prognostic biomarker in ENKTL
Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, discusses EGR1 as a potential prognostic marker in extranodal NK/T-cell lymphoma (ENKTL). Gene expression profiling has shown EGR1 to be a promising prognostic biomarker and can also be activated by LMP1 or the Epstein–Barr virus (EBV). Whilst pembrolizumab and nivolumab are effective treatments, half of patients fail to respond to treatment. Therefore, new biomarkers such as EGR1 are necessary in developing novel effective treatments for ENKTL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
